Keene Wei
Chief Executive Officer Vitsgen Therapeutics, Inc.
Serial entrepreneur, deeply engaged across the full chain of drug discovery, CMC & compliance, regulatory strategy and marketing;
Founded VitsGen in 2021, focusing on the development of targeted radionuclide drug conjugates (RDCs);
Founded Viwit in 2006, specializing in Boranes, Drug Substances and Drug Products, as well as new drug R&D and manufacturing ~ with three production sites and multiple products approved by US FDA and China NMPA;
Previously served as Research Scientist at Bristol-Myers Squibb and Director of the Chemistry PepTech Corporation (USA);
PhD Dartmouth College, BS Peking University.
Seminars
Validating novel targets remains costly and time-consuming, while a wealth of clinical evidence already exists across ADCs, T-cell engagers, bispecifics, and other targeted therapies.
This workshop will explore how to assess targets validated outside radiopharmaceuticals and determine when there is sufficient evidence to justify progression into an RLT program.
- Mining other modalities for targets: What can we learn from ADCs, T-cell engagers, bispecifics, and other targeted therapies to identify clinically validated targets with potential for RPT?
- Determining what translates: Which target characteristics and clinical data are genuinely transferable, and where do RPT requirements diverge across target accessibility, expression density, internalization, heterogeneity, biodistribution, and normal-tissue uptake?
- Building a cross-modality target-selection framework: Define the evidence required to confidently progress a clinically validated target into RPT, identify the additional RPT-specific validation needed and establish
- Explore the rationale for selecting novel targets with therapeutic potential beyond established RLT targets
- Apply lessons learned from advancing PSMA and FAP programs into clinical development to inform target selection and candidate optimization
- Leverage insights from PSMA and FAP around affinity, internalization, tumor uptake and retention to guide the design of next-generation candidates
